About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 935 record(s)
Req # A-2021-001787
Adverse Drug Reaction (ADR) for AGALSIDASE BETA. Report number: E2B_04595165.Organization: Health Canada
January 2024
Req # A-2022-000123
Adverse Drug Reaction (ADR) for ALFUZOSIN HYDROCHLORIDE. Report number: E2B_05007203.Organization: Health Canada
January 2024
Req # A-2023-000126
Adverse Drug Reactions (ADRs). Report numbers: E2B_00675714, E2B_02977829, E2B_03128456.Organization: Health Canada
January 2024
Req # A-2023-001017
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107682-242, Deputy Ministerial Meeting with Helium Developers Association of Canada.Organization: Health Canada
January 2024
Req # A-2023-001167
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-109485-722, Deputy Ministerial Meeting with the President and Chief Executive Officer of The Ottawa Hospital.Organization: Health Canada
January 2024
Req # A-2023-000483
A list of every drug approved under Health Canada's Special Access Program (SAP) between January 1, 2018 and July 6, 2023.Organization: Health Canada
January 2024
Req # A-2023-000968
Information on the intended use of a device listed on Medical Device Active License Listing (MDALL). Requesting it for the following: Licence No.: 95942, Type: System, Device class: 2, Device first issue date 2015-10-15, Licence name: VIASURE, Device first issue date: 2015-10-15, Device name: OW100 - APPLICATORS, Identifier first issue date: 2015-10-15, Device identifiers: OE035, OE050, OP155 and Device first issue date: 2021-08-05, Device name - VIASURE, Identifier first issue date: 2021-08-05, Device identifiers: 1000017.Organization: Health Canada
January 2024
Req # A-2023-00135
All records and correspondence regarding the accreditation of CFIA's Ottawa Laboratory (960 Carling Ave., Bldg. 22 Ottawa, ON K1A 0C6) with the International Olive Oil Council (IOC).Organization: Canadian Food Inspection Agency
December 2023
Req # A-2023-00160
Records regarding the hiring of EG-02 and EG-03 positions, including emergency hiring, within Ontario Operations Animal Health, Meat Hygiene, and Plant Health divisions, from April 1, 2020 to October 31, 2023.Organization: Canadian Food Inspection Agency
December 2023
Req # A-2023-000675
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_02229369, E2B_02381693, E2B_02396904, E2B_02504551, E2B_01438894, E2B_02504551, E2B_02381693, E2B_02760591, E2B_02511273, E2B_01497636.Organization: Health Canada
December 2023